Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation18-05-2023
18-05-2023
Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of board meeting18-05-2023
Zydus Lifesciences Ltd - 532321 - Corporate Action-Board approves Dividend
Outcome of Board meeting18-05-2023
Zydus Lifesciences Ltd - 532321 - Audited Financial Results For The Year Ended March 31, 2023
Audited Financial Results For The Year Ended March 31, 202318-05-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection17-05-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201516-05-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q4 FY23 post results earning call details13-05-2023
Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Notice For The Meeting Of Board Of Directors
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2023 ,inter alia, to consider and approve apart from other agenda items, approval of audited financial results for the quarter / year ended on March 31, 2023 and to recommend final dividend for the financial year ended on March 31, 2023.12-05-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives EIR for the Pre-Approval Inspection (PAI) at the manufacturing facility in Moraiya, Ahmedabad10-05-2023